In a webinar hosted by the United Mitochondrial Disease Foundation (UMDF), Cyclerion will discuss promising Phase 2a clinical study of CY6463, a first-in-class CNS- penetrant sGC stimulator, in participants with Mitochondrial Encephalomyopathy, Lactic Acidosis and Stroke-like episodes (MELAS).

Mitochondrial disease clinician-researcher, Amel Karaa, M.D., Assistant Professor and Director of the Mitochondrial Disease Program and Lysosomal Disorders Program at Harvard Medical School and Massachusetts General Hospital, and 2013 UMDF fellow, will discuss the implications and potential future impact of these encouraging data on patients with MELAS.